<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="case-report" dtd-version="1.0" xml:lang="HR" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-142-29</article-id>
<article-id pub-id-type="doi">10.26800/LV-142-1-2-8</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Case report</subject></subj-group>
</article-categories>
<title-group>
<article-title>Kvartarna prevencija. Predijabetes: rizik, bolest ili suvi&#x0161;na dijagnoza?</article-title>
<subtitle>Bolesti koje ne donose veliku opasnost ne treba dra&#x017E;iti ljekarijama.</subtitle>
<subtitle>(Platon, 5. st. pr. n. e. U: Timej: Matica hrvatska 2017., str. 27., prijevod Damira Barbari&#x0107;a)</subtitle>
<trans-title-group xml:lang="en">
<trans-title>Quaternary prevention. Prediabetes: risk, disease or overdiagnosis?</trans-title>
<trans-subtitle>The diseases which are not of great danger should not be teased by medicines</trans-subtitle>
<trans-subtitle>(Plato, 5<sup>th</sup> century BC)</trans-subtitle>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6353-4646</contrib-id><name><surname>Botica</surname><given-names>Marija Vrca</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pavli&#x0107;-Renar</surname><given-names>Ivana</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<aff id="aff1"><label>1</label>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu</aff>
<aff id="aff2"><label>2</label>Dom zdravlja Zagreba&#x010D;ke &#x017E;upanije</aff>
</contrib-group>
<author-notes><corresp id="cor1">Adresa za dopisivanje: Prof. dr. sc. Marija Vrca Botica, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-6353-4646">https://orcid.org/0000-0002-6353-4646</ext-link> Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu, Dom zdravlja Zagreba&#x010D;ke &#x017E;upanije, 10000 Zagreb; e-po&#x0161;ta: <email xlink:href="vrcabotica@yahoo.com">vrcabotica@yahoo.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>02</month><year>2020</year></pub-date>
<volume>142</volume>
<issue>1-2</issue>
<fpage>29</fpage>
<lpage>32</lpage>
<permissions>
<copyright-year>2020</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Kvartarna prevencija suvremen je, kriti&#x010D;ki pristup moderne medicine. Usmjerena je na za&#x0161;titu pacijenata od medicinskih intervencija koje su suvi&#x0161;ne pri zdravstvenoj za&#x0161;titi i mogu nanijeti vi&#x0161;e &#x0161;tete nego koristi. Kvartarna prevencija sastavni je dio svih triju prevencija: primarne, sekundarne i tercijarne. Cilj je za&#x0161;tita pacijenta od mogu&#x0107;ega suvi&#x0161;nog probira, suvi&#x0161;ne dijagnoze bolesti, &#x0161;to pacijenta mo&#x017E;e uvesti u suvi&#x0161;nu medikalizaciju i postupke. Dijabetes je kroni&#x010D;na, do&#x017E;ivotna bolest s dijagnozom na temelju dogovorene to&#x010D;ke razgrani&#x010D;enja kontinuirane varijable i pod visokim je rizikom od suvi&#x0161;nih postupaka. S druge strane, prepoznavanjem i intervencijom u grani&#x010D;nim podru&#x010D;ju (u predbolesti) mo&#x017E;e se odgoditi nastanak bolesti. Izazov je prepoznati rizike i uvesti intervenciju samo ondje gdje su oni visoki, gdje je nastanak bolesti siguran, a odgovaraju&#x0107;a intervencija mo&#x017E;e ga odgoditi. &#x010C;ini li se to za osobe niskog rizika od nastanka bolesti i komplikacija, pacijentu se ne mijenja prognoza, ali mu se dodaju suvi&#x0161;na dijagnoza i dodatni postupci te izaziva dodatni stres. O ovomu treba voditi ra&#x010D;una na svim razinama zdravstvene za&#x0161;tite, no poglavito u obiteljskoj medicini, &#x0161;to je prepoznala i Svjetska udruga obiteljskih lije&#x010D;nika (WONCA).</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Quaternary prevention is a contemporary critical approach to modern medicine. Its goal is the protection of patients from unnecessary medical intervention which can do more harm than good. Quaternary prevention is a part of all three preventions: primary, secondary and tertiary. Its aim is to protect a patient from overscreening and overdiagnosis which can lead to overmedicalization. As a life-long disease with diagnosis based on the agreed cutoff point of a continuous variable, diabetes is in a great risk of over-intervention. However, with a right intervention in pre-disease it is possible to postpone the disease. The challenge is to recognize the risks and intervene if they are high, the risk of disease progression is substantial, and appropriate intervention can diminish it. If the same is done for low risk it is a waste of energy and means, and the patient gains nothing but additional stress due to overdiagnosis. It has to be considered at all levels of health care, but mostly in primary care, which has been recognized by the international association of family physicians (WONCA).</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori SUVI&#x0160;NI ZDRAVSTVENI POSTUPCI</kwd><kwd>PREVENTIVNE ZDRAVSTVENE SLU&#x017D;BE &#x2013; metode</kwd><kwd>PREDIJABETES &#x2013; dijagnoza</kwd><kwd>DIJABETES TIP 2 &#x2013; prevencija i kontrola</kwd><kwd>PROBIR &#x2013; metode</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>MEDICAL OVERUSE</kwd><kwd>PREVENTIVE HEALTH SERVICES &#x2013; methods</kwd><kwd>PREDIABETIC STATE &#x2013; diagnosis</kwd><kwd>DIABETES MELLITUS, TYPE 2 &#x2013; prevention and control</kwd><kwd>MASS SCREENING &#x2013; methods</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Znanja i mogu&#x0107;nosti lije&#x010D;enja kroni&#x010D;nih bolesti, kao i sve ve&#x0107;i pritisci da se &#x201E;lije&#x010D;i&#x201C; rizik i kada to nije potrebno nala&#x017E;u dublje razumijevanje i provedbu racionalne kvartarne prevencije (P4).</p>
<p>P4 te&#x017E;i prevenciji ovih postupaka: (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>)</p>
<list id="L1" list-type="bullet"><list-item><p>suvi&#x0161;na dijagnoza (engl. <italic>Overdiagnosis</italic>) nepotrebno je dodjeljivanje dijagnoze predijagnozi (engl. <italic>Predisease</italic>), stanju ili rizicima koji se tek mogu razviti u bolest, mogu do&#x017E;ivotno ostati nepromijenjeni, imati malu vjerojatnost razvoja u bolest, polako se mijenjati ili zavr&#x0161;iti samoreguliraju&#x0107;im ishodom</p></list-item>
<list-item><p>suvi&#x0161;ni probir (engl. <italic>Overerdetection</italic>, <italic>Overscreening</italic>) jest probir bez indikacije: odre&#x0111;ivanje abnormalnosti koje vjerojatno nikad ne&#x0107;e &#x0161;tetiti, koje su minimalno progresivne ili to nisu, koje su samoreguliraju&#x0107;e i ako je eventualno otkrivenu bolest nemogu&#x0107;e lije&#x010D;iti. Suvi&#x0161;an je i ponavljani probir na rizike od bolesti za koje je prethodno dokazano da ne postoje ili je malena vjerojatnost da &#x0107;e nastati</p></list-item>
<list-item><p>suvi&#x0161;ni zdravstveni postupci (engl. <italic>Overuse</italic>) nepotrebna su uporaba zdravstvenih servisa od pacijenta i lije&#x010D;nika</p></list-item>
<list-item><p>suvi&#x0161;na medikalizacija (engl. <italic>Over-medicalisation</italic>) jest dodavanje lijekova nemedicinskom problemu</p></list-item>
<list-item><p>suvi&#x0161;na informacija (engl. <italic>Overinformation</italic>) optere&#x0107;enje je populacije suvi&#x0161;nim informacijama, onima koje nemaju posljedi&#x010D;ne korisne postupke ili poti&#x010D;u nepotrebne postupke, a pacijent ih &#x010D;esto ne razumije pa izazivaju stres</p></list-item>
<list-item><p>suvi&#x0161;ni marketing farmaceutike (engl. <italic>Overselling</italic>) neprimjerena je propaganda suvi&#x0161;ne dijagnoze ili lije&#x010D;enja.</p></list-item></list>
<p>P4 sastavni je dio primarne, sekundarne i tercijarne prevencije. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) Njegov je cilj eti&#x010D;ki prihvatljiv i koristan postupak (eti&#x010D;ki prihvatljiva zamjena umjesto nepotrebne intervencije). (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r6"><italic>6</italic></xref>&#x2013;<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) On je temelj susreta pacijenta i lije&#x010D;nika obiteljske medicine, ali treba biti sastavnica svih razina zdravstvene za&#x0161;tite. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>)</p>
<p>U odnosima izme&#x0111;u lije&#x010D;nika i pacijenta P4 je vi&#x0161;e usmjeren lije&#x010D;niku, poti&#x010D;e strukturirani (zatvoreni) nadzor, raspravu prema odre&#x0111;enim aktivnostima temeljenima na dokazima prema principu &#x201E;najprije ne &#x0161;tetiti&#x201C;.</p>
<p>Kvantificirani postupci kvartarne prevencije nisu razra&#x0111;eni niti su mjerljivi njezini ishodi i u&#x010D;inci. Smjerovi razvoja P4 jesu utvr&#x0111;ivanje situacija koje vode u suvi&#x0161;nu dijagnozu, intervenciju i medikalizaciju, razvijanje komunikacijskih vje&#x0161;tina i kriti&#x010D;ko stajali&#x0161;te prema smjernicama i sukobu interesa, nala&#x017E;enje zamjena za nepotrebnu medicinsku intervenciju i razvoj alata za identifikaciju P4 u za&#x0161;titi te za mjerne instrumente ishoda P4. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>)</p>
<p>Problemi s dijagnozama temeljenima na kontinuiranoj varijabli jesu kako odrediti prijelomnu to&#x010D;ku i &#x0161;to u&#x010D;initi s grani&#x010D;nim vrijednostima. Grani&#x010D;ne su vrijednosti temelj pojma predbolesti pa se tako govori i o stanju koje prethodi dijabetesu, tj. predijabetesu. Dobrobit probira jest mogu&#x0107;nost prevencije bolesti i razvoja njezinih komplikacija.</p>
<p>Donedavno je jedini kriterij predijabetesa bila o&#x0161;te&#x0107;ena tolerancija glukoze (engl. <italic>Impaired glucose tolerance</italic> &#x2013; IGT), mjerena dvosatnim oralnim testom optere&#x0107;enja glukozom (engl. <italic>2 hour Oral Glucose Tolerance Test</italic> &#x2013; 2-h OGTT): 7,8 &#x2013; 11,1 mmol/L. Posljednjih se godina, prema preporuci ADA-e (engl. <italic>American Diabetes Association</italic>), upotrebljavaju povi&#x0161;ena vrijednost glikemije nata&#x0161;te (engl. <italic>Impaired fasting glucose</italic> &#x2013; IFG), 5,6 &#x2013; 6,9 mmol/L, ali i glikirani hemoglobin (HbA<sub>1c</sub>). Razli&#x010D;ite me&#x0111;unarodne organizacije predla&#x017E;u razli&#x010D;ite kriterije (<xref ref-type="table" rid="t1">Table 1</xref>). (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>, <xref ref-type="bibr" rid="r11"><italic>11</italic></xref>, <xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) Novi biomarkeri imaju smisla ako obja&#x0161;njavaju klini&#x010D;ki status i simptome i ako tretman &#x010D;ine klini&#x010D;ki i prognosti&#x010D;ki boljim. Me&#x0111;utim, rizik od suvi&#x0161;ne dijagnoze vi&#x0161;i je s brojem biomarkera (ovdje HbA<sub>1c</sub>), a biomedicinski parametri odvajaju se od pacijenta i ukupnoga klini&#x010D;kog statusa. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r3"><italic>3</italic></xref>)</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Diagnostic criteria of prediabetes according ADA and WHO guidelines</title>
</caption>
<table frame="hsides" rules="groups">
<col width="39.03%"/>
<col width="30.47%"/>
<col width="30.5%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Dijagnosti&#x010D;ki kriterij<break/>/ Diagnostic criteria</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">ADA*</th>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">SZO</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Naziv / Name</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Predijabetes<break/>/ Prediabetes</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Nedijabeti&#x010D;ka hiperglikemija<break/>/ Non-diabetic<break/>hyperglycemia</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">O&#x0161;te&#x0107;ena tolerancija glukoze nakon 120 min / 75 g glukoze nata&#x0161;te<break/>Impaired glucose tolerance<break/>(120 min after 75 g oral glucose load)</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">7,8 &#x2013; 11,0 mmol/L</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">7,8 &#x2013; 11,0 mmol/L</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">O&#x0161;te&#x0107;ena glukoza nata&#x0161;te<break/>/ Impaired fasting glucose</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">5,6 &#x2013; 6,9 mmol/L*</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">6,1 &#x2013; 6,9 mmol/L</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">HbA<sub>1c</sub> / A1c**</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">5,7 &#x2013; 6,4%</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt"></td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>* Prema smjernicama ADA-e za potvrdu je dovoljan samo jedan od tri kriterija u dva neovisna uzorka. / According to ADA, diagnosis requires two abnormal test results from the same sample or in two separate test samples.</p>
<p>** Za dijagnozu predijabetesa posebno je dvojbena upotreba HbA<sub>1c</sub>. Kao samostalni test ne rabi se pri izvo&#x0111;enju probira za predijabetes i &#x0161;e&#x0107;ernu bolest. Ulazi u procjenu predijabetesa, jer HbA<sub>1c</sub> &#x2265; 6,0% i vi&#x0161;e zna&#x010D;i vi&#x0161;i rizik od kardiovaskularnih bolesti. / There are concerns about the use of A1C in screening for prediabetes and diabetes. It is a part of assessment of prediabetes since A1C &#x2265; 6.0% is associated with an increased cardiovascular risk.</p>
</table-wrap-foot></table-wrap>
<p>Godine 2017. Me&#x0111;unarodna dijabeti&#x010D;ka federacija (engl. <italic>International Diabetes Federation</italic> &#x2013; IDF) procijenila je prevalenciju predijabetesa (IGT na populaciji od 20 do 79 godina) na 7,3% ili 352 milijuna ljudi. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) Procjena prevalencije ovisi o dijagnosti&#x010D;kim kriterijima i populaciji na kojoj se procjenjuje. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>, <xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Studija CroDiab GP, provedena 2010. u Hrvatskoj (2 neovisne vrijednosti IFG-a; populacija od 45 do 70 godina) pokazala je prevalenciju predijabetesa od 23% uz IFG 6,1 &#x2013; 6,9 mmol/L i od 30,2% uz IFG 5,6 &#x2013; 6,9 mmol/L. Ra&#x010D;una se da progresija predijabetesa u &#x0161;e&#x0107;ernu bolest, prema novim kriterijima, iznosi 2% na godinu. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>&#x2013;<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>)</p>
<p>Dijabetes zadovoljava preduvjete za probir: ima epidemiolo&#x0161;ko i javnozdravstveno zna&#x010D;enje, otkriva se standardiziranim postupcima, otkrivena bolest mo&#x017E;e se lije&#x010D;iti. Prija&#x0161;nji se probir radio odre&#x0111;ivanjem glukoze nata&#x0161;te svima starijima od 40 godina (populisti&#x010D;ki ili univerzalni probir). Nakon nekoliko provedenih studija sugeriran je drugi pristup, usredoto&#x010D;en samo na osobe povi&#x0161;enog rizika. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>)</p>
<p>Program prevencije dijabetesa (engl. <italic>Diabetes Prevention Program</italic> &#x2013; DPP) dokazao je da promjene &#x017E;ivotnih navika u predijabetesu mogu odgoditi dijabetes. Poslije intenzivne intervencije progresija predijabetesa u dijabetes smanjena je za 36% (uz metformin) i za 54% (uz promjenu &#x017E;ivotnih navika) tijekom 2,8 godina u odnosu prema standardnom tretmanu. (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) Pacijenti su probrani prema 2-h OGTT-u, a ne prema vrijednostima glikiranog hemoglobina (HbA<sub>1c</sub>) ili glukoze u krvi nata&#x0161;te (engl. <italic>Fasting plasma glucose</italic> &#x2013; FPG). Prema tomu, broj osoba s 3 godine intervencije za sprje&#x010D;avanje jednog dijabetesa jest 13,9 uz metformin, a 6,9 uz intenzivnu promjenu &#x017E;ivotnih navika. I druge su studije to potvrdile. Na temelju tih rezultata pokrenuti su programi prevencije dijabetesa u raznim sredinama. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r17"><italic>17</italic></xref>)</p>
<p>Najbolji u&#x010D;inak posti&#x017E;e se promjenom &#x017E;ivotnog stila. Programi prevencije slo&#x017E;ene su, multidisciplinarne i skupe aktivnosti (ne uklju&#x010D;uju samo uobi&#x010D;ajeno savjetovanje), a adherencija pacijenata varijabilna je. U stvarnom &#x017E;ivotu strukturirani dugoro&#x010D;ni programi promjene &#x017E;ivotnih navika uglavnom su nedostupni. Institucionalnu tjelesnu aktivnost osiguravaju&#x0107;a dru&#x0161;tva ne pla&#x0107;aju. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Stoga metformin ulazi u smjernice: razmatra se u mla&#x0111;ih od 60 godina, s ITM-om od najmanje 35 kg/m<sup>2</sup> i uz prethodni gestacijski dijabetes (prate&#x0107;i vitamin B<sub>12</sub>, prema potrebi uz supstituciju). Me&#x0111;utim, ako se metformin preporu&#x010D;i osobama niskog i srednjeg rizika, uzimali bi ga milijuni ljudi: dodatnih 50% odraslih Kineza i 37% odraslih Amerikanaca. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Parametar pra&#x0107;enja intervencije nije jasan. Tjelesna te&#x017E;ina? Razine glikemije? Krajnji je cilj odgoda nastanka &#x0161;e&#x0107;erne bolesti i kardiovaskularnih doga&#x0111;aja u dugoro&#x010D;nom pra&#x0107;enju.</p>
<p>Prema englesko-njema&#x010D;ko-nizozemskoj studiji ADDITION, optimalno mjesto za probir jest ordinacija obiteljske medicine, i to zbog prigodnog (oportunisti&#x010D;kog) probira. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>)</p>
<p>Prigodni probir ima dvije faze: prijekonzultacijsku i konzultacijsku. U prijekonzultacijskoj fazi pacijenti s rizikom od dijabetesa &#x201E;obilje&#x017E;avaju&#x201C; se na temelju dokumentacije. Pri njihovu sljede&#x0107;em posjetu (bez obzira na razlog) nastupa konzultacijska faza. Naime, tada treba uvjetno zdravog pacijenta uvjeriti u dobrobit dugoro&#x010D;ne intervencije u odnosu prema &#x201E;&#x010D;ekanju&#x201C; bolesti i naknadnom lije&#x010D;enju. Dvojbe imaju i pacijent i lije&#x010D;nik. Suradnja je bolja ako lije&#x010D;nik ne postupa agresivno i autoritativno, ako rizik ne pretvara u bolest. Objasnit &#x0107;e pojam rizika i dogovoriti testiranje glukoze nata&#x0161;te u dva neovisna mjerenja ili OGTT-om. Tri su ishoda i, ovisno o njima, intervencije:</p>
<list id="L2" list-type="order"><list-item><p>Uredan nalaz glukoze nata&#x0161;te do 5,6 mmol/L. Kontrola za 3 godine, uklanjanje prethodno prepoznatih promjenjivih rizika. Razvoj komplikacija malo je vjerojatan, &#x010D;ak i ako se bolest pojavi u tom razdoblju.</p></list-item>
<list-item><p>Povi&#x0161;ena razina glukoze nata&#x0161;te: 5,6 &#x2013; 6,9 mol/L. Provodi se oralni test optere&#x0107;enja glukozom (OGTT). Tu dolazimo do grani&#x010D;ne dijagnoze &#x2013; predijabetesa. Preporu&#x010D;uju se promjena &#x017E;ivotnih navika i kontrola za godinu dana.</p></list-item>
<list-item><p>Dijabetes: 7,0 i vi&#x0161;e mmol/L. Provodi se lije&#x010D;enje prema algoritmu lije&#x010D;enja.</p></list-item></list>
<p>Ovakvim pristupom smanjuju se broj pozvanih pacijenata (engl. <italic>Number needed to invite</italic> &#x2013; NNI) i broj testiranih (engl. <italic>Number needed to screen</italic> &#x2013; NNS) za jedan novootkriveni dijabetes. Godi&#x0161;nja progresija predijabetesa u &#x0161;e&#x0107;ernu bolest iznosi 5 &#x2013; 10%. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>, <xref ref-type="bibr" rid="r16"><italic>16</italic></xref>, <xref ref-type="bibr" rid="r17"><italic>17</italic></xref>)</p>
<p>Populacijski, treba provesti primarnu prevenciju &#x2013; poticati zdrav na&#x010D;in &#x017E;ivota, &#x0161;to je multisektorska akcija, koja uklju&#x010D;uje ne samo primarnu prevenciju dijabetesa nego i spektra kardiovaskularnih bolesti &#x0161;to su glavni uzrok mortaliteta.</p>
<p>Pacijentima s nepotpunim kriterijima predijabetesa nadzor se &#x010D;ini nepotrebnim. Zbog suvi&#x0161;ne dijagnoze raste broj konzultacija primarne i sekundarne za&#x0161;tite do 78%. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Pacijente s predijabetesom treba prigodno nadzirati, &#x0161;to zna&#x010D;i provjeravati provo&#x0111;enje preporuka dobivenih savjetovanjem, stanje tjelesne te&#x017E;ine, navika itd., i to pri svakom posjetu, bez obzira na razlog.</p>
<p>Svjetska udruga obiteljskih lije&#x010D;nika (WONCA) donijela je 2018. godine deklaraciju u kojoj je nagla&#x0161;ena va&#x017E;nost suvi&#x0161;ne dijagnoze i njezinih posljedica. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>)</p>
</body>
<back>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brodersen</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>LM</given-names></name><name><surname>Heneghan</surname><given-names>C</given-names></name><etal/></person-group> <article-title>Overdiagnosis: what it is and what it isn&#x2019;t.</article-title> <source>BMJ Evid Based Med</source>. <year>2018</year>;<volume>23</volume>:<fpage>1</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1136/ebmed-2017-110886</pub-id><pub-id pub-id-type="pmid">29367314</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>C</given-names></name><name><surname>Godycki-Cwirko</surname><given-names>M</given-names></name><name><surname>Heleno</surname><given-names>B</given-names></name><name><surname>Brodersen</surname><given-names>J</given-names></name></person-group>. <article-title>Quaternary prevention: reviewing the concept.</article-title> <source>Eur J Gen Pract</source>. <year>2018</year>;<volume>24</volume>:<fpage>106</fpage>&#x2013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1080/13814788.2017.1422177</pub-id><pub-id pub-id-type="pmid">29384397</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>J-M</given-names></name><name><surname>Jamoulle</surname><given-names>M</given-names></name></person-group>. <article-title>Primary care physicians&#x2019; action plans for responding to results of screening tests based on the concept of quaternary prevention.</article-title> <source>J Prev Med Public Health</source>. <year>2016</year>;<volume>49</volume>:<fpage>343</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3961/jpmph.16.059</pub-id><pub-id pub-id-type="pmid">27951627</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamoulle</surname><given-names>M</given-names></name></person-group>. <article-title>Quaternary prevention, an answer of family doctors to overmedicalization.</article-title> <source>Int J Health Policy Manag</source>. <year>2015</year>;<volume>4</volume>:<fpage>61</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.15171/ijhpm.2015.24</pub-id><pub-id pub-id-type="pmid">25674569</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Kirchhoff</surname><given-names>AC</given-names></name><name><surname>Morden</surname><given-names>NE</given-names></name><etal/></person-group> <article-title>Physician response to patient request for unnecessary care.</article-title> <source>Am J Manag Care</source>. <year>2015</year>;<volume>21</volume>:<fpage>823</fpage>&#x2013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">26633255</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeli&#x0107; Bari&#x010D;evi&#x0107;</surname><given-names>I</given-names></name><name><surname>Vrca Botica</surname><given-names>M</given-names></name><name><surname>Pavli&#x0107; Renar</surname><given-names>I</given-names></name></person-group>. <article-title>Kvartarna prevencija kao temelj racionalnog pristupa pacijentu u obiteljskoj medicini.</article-title> <source>Lijec Vjesn</source>. <year>2014</year>;<volume>136</volume>:<fpage>152</fpage>&#x2013;<lpage>5</lpage>.</mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamoulle</surname><given-names>M</given-names></name></person-group>. <article-title>Quaternary prevention: first, do not harm.</article-title> <source>Rev Bras Med Fam Comunidade</source>. <year>2015</year>;<volume>10</volume>:<fpage>1</fpage>.</mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Widmer</surname><given-names>D</given-names></name><name><surname>Herzig</surname><given-names>L</given-names></name><name><surname>Jamoulle</surname><given-names>M</given-names></name></person-group>. <article-title>Quaternary prevention: is acting always justified in family medicine?</article-title> <source>Rev Med Suisse</source>. <year>2014</year>;<volume>10</volume>(<issue>430</issue>):<fpage>1052</fpage>&#x2013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">24930150</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depallens</surname><given-names>MA</given-names></name><name><surname>de Medeiros Guimar&#x00E3;es</surname><given-names>JM</given-names></name><name><surname>Filho</surname><given-names>NA</given-names></name></person-group>. <article-title>Quaternary prevention: Is this concept relevant to public health? A bibliometric and descriptive content analysis.</article-title> <source>BMJ Yale Med Rxiv</source>. <year>2019</year>;<volume>19007526</volume>: <pub-id pub-id-type="doi">10.1101/19007526</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>B</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Matsushita</surname><given-names>K</given-names></name><etal/></person-group> <article-title>Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.</article-title> <source>Lancet Diabetes Endocrinol</source>. <year>2017</year>;<volume>5</volume>:<fpage>34</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(16)30321-7</pub-id><pub-id pub-id-type="pmid">27863979</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="web">International Diabetes Federation. IDF Diabetes Atlas 2019. 9. izd. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.diabetesatlas.org">www.diabetesatlas.org</ext-link>. Pristupljeno: 28. 10. 2019.</mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hostalek</surname><given-names>U</given-names></name></person-group>. <article-title>Global epidemiology of prediabetes - present and future perspectives.</article-title> <source>Clin Diabetes Endocrinol</source>. <year>2019</year>;<volume>5</volume>:<fpage>5</fpage>. <pub-id pub-id-type="doi">10.1186/s40842-019-0080-0</pub-id><pub-id pub-id-type="pmid">31086677</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrca Botica</surname><given-names>M</given-names></name><name><surname>Carkaxhiu</surname><given-names>L</given-names></name><name><surname>Kern</surname><given-names>J</given-names></name><etal/></person-group> <article-title>How to improve opportunistic screening by using EMRs and other data. The prevalence of undetected diabetes mellitus in target population in Croatia.</article-title> <source>Public Health</source>. <year>2017</year>;<volume>145</volume>:<fpage>30</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.puhe.2016.12.008</pub-id><pub-id pub-id-type="pmid">28359387</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>. <article-title>2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019.</article-title> <source>Diabetes Care</source>. <year>2019</year>;<volume>42</volume> <supplement>Suppl. 1</supplement>:<fpage>S13</fpage>&#x2013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.2337/dc19-S002</pub-id><pub-id pub-id-type="pmid">30559228</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knowler</surname><given-names>WC</given-names></name><name><surname>Barrett-Connor</surname><given-names>E</given-names></name><name><surname>Fowler</surname><given-names>SE</given-names></name><etal/><collab>Diabetes Prevention Program Research Group</collab></person-group>. <article-title>Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.</article-title> <source>N Engl J Med</source>. <year>2002</year>;<volume>346</volume>:<fpage>393</fpage>&#x2013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa012512</pub-id><pub-id pub-id-type="pmid">11832527</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>B</given-names></name><name><surname>Absetz</surname><given-names>P</given-names></name><name><surname>Dunbar</surname><given-names>JA</given-names></name><name><surname>Reddy</surname><given-names>P</given-names></name><name><surname>O&#x2019;Neil</surname><given-names>A</given-names></name></person-group>. <article-title>The spread and uptake of diabetes prevention programs around the world: a case study from Finland and Australia.</article-title> <source>Transl Behav Med</source>. <year>2011</year>;<volume>1</volume>:<fpage>270</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1007/s13142-011-0046-y</pub-id><pub-id pub-id-type="pmid">21765880</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aziz</surname><given-names>Z</given-names></name><name><surname>Absetz</surname><given-names>P</given-names></name><name><surname>Oldroyd</surname><given-names>J</given-names></name><name><surname>Pronk</surname><given-names>NP</given-names></name><name><surname>Oldenburg</surname><given-names>B</given-names></name></person-group>. <article-title>A systematic review of real-world diabetes prevention programs: learnings from the last 15 years.</article-title> <source>Implement Sci</source>. <year>2015</year>;<volume>10</volume>:<fpage>172</fpage>. <pub-id pub-id-type="doi">10.1186/s13012-015-0354-6</pub-id><pub-id pub-id-type="pmid">26670418</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dall</surname><given-names>TM</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Halder</surname><given-names>P</given-names></name><etal/></person-group> <article-title>The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes.</article-title> <source>Diabetes Care</source>. <year>2014</year>;<volume>37</volume>:<fpage>3172</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2337/dc14-1036</pub-id><pub-id pub-id-type="pmid">25414388</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>RK</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Lauritzen</surname><given-names>T</given-names></name><etal/></person-group> <article-title>A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in people with screen-detected diabetes in primary care (ADDITION-Europe) study.</article-title> <source>Health Technol Assess</source>. <year>2016</year>;<volume>20</volume>:<fpage>1</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.3310/hta20640</pub-id><pub-id pub-id-type="pmid">27583404</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="web">Europe W. Overdiagnosis And Action to Be Taken &#x2013; Position Paper 2018. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.woncaeurope.org/content/overdiagnosis-and-action-to-be-taken-%E2%80%93-position-paper-2018">https://www.woncaeurope.org/content/overdiagnosis-and-action-to-be-taken-%E2%80%93-position-paper-2018</ext-link>. Pristupljeno: 29. studeni 2019.</mixed-citation></ref>
</ref-list>
</back>
</article>
